意大利的 COVID-19 临床试验：呼吁简单化、高标准和全球资源共享。
COVID-19 trials in Italy: A call for simplicity, top standards and global pooling.
机构信息
ANMCO Research Center, Florence, Italy.
Physician Scientist, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
出版信息
Int J Cardiol. 2020 Nov 1;318:160-164. doi: 10.1016/j.ijcard.2020.06.043. Epub 2020 Jun 28.
Abstract
The novel coronavirus disease, affecting ~9 million people in the past five months and causing >460,000 deaths worldwide, is completely new to mankind. More than 2,000 research projects registered at ClinTrials.gov are aiming at finding effective treatments for rapid transfer to clinical practice. Unfortunately, just few studies have a sufficiently valid design to provide reliable information for clinical practice.
摘要
在过去的五个月里，新型冠状病毒病影响了全球约 900 万人，导致超过 46 万人死亡，这种疾病对人类来说是全新的。在 ClinTrials.gov 上注册的 2000 多个研究项目旨在寻找有效的治疗方法，以便迅速推向临床实践。不幸的是，只有少数研究具有足够有效的设计，能够为临床实践提供可靠的信息。
相似文献
1
COVID-19 trials in Italy: A call for simplicity, top standards and global pooling.意大利的 COVID-19 临床试验：呼吁简单化、高标准和全球资源共享。
Int J Cardiol. 2020 Nov 1;318:160-164. doi: 10.1016/j.ijcard.2020.06.043. Epub 2020 Jun 28.
2
Panic prescribing has become omnipresent during the COVID-19 pandemic.在新冠疫情期间，恐慌性开药现象已无处不在。
J Clin Invest. 2020 Jun 1;130(6):2752-2753. doi: 10.1172/JCI139562.
3
Current therapies under investigation for COVID-19: potential COVID-19 treatments.正在研究的 COVID-19 治疗方法：有潜力的 COVID-19 治疗方法。
Can J Physiol Pharmacol. 2020 Aug;98(8):483-489. doi: 10.1139/cjpp-2020-0286. Epub 2020 Jul 8.
4
Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis.评估 COVID-19 治疗方法的注册临床试验特征：一项横断面分析。
BMJ Open. 2020 Jun 9;10(6):e039978. doi: 10.1136/bmjopen-2020-039978.
5
COVID-19: A Defining Moment for Clinical Pharmacology?新型冠状病毒肺炎：临床药理学的决定性时刻？
Clin Pharmacol Ther. 2020 Jul;108(1):11-15. doi: 10.1002/cpt.1876.
6
Anticovid, a comprehensive open-access real-time platform of registered clinical studies for COVID-19.“抗新冠”，一个关于新冠病毒病注册临床研究的综合性开放获取实时平台。
J Antimicrob Chemother. 2020 Sep 1;75(9):2708-2710. doi: 10.1093/jac/dkaa223.
7
COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer?新冠疫情：药物制剂与药物递送专家能提供什么？
Pharm Dev Technol. 2020 Jul;25(6):649. doi: 10.1080/10837450.2020.1764670.
8
[Real-life data and Covid-19: The third avenue of reseach].[真实世界数据与新冠疫情：第三条研究途径]
Encephale. 2020 Jun;46(3S):S114-S115. doi: 10.1016/j.encep.2020.04.003. Epub 2020 Apr 22.
9
Repurposing Existing Drugs for the Treatment of COVID-19.重新利用现有药物治疗 COVID-19。
Ann Am Thorac Soc. 2020 Oct;17(10):1186-1194. doi: 10.1513/AnnalsATS.202005-566FR.
10
A Call for Pediatric COVID-19 Clinical Trials.呼吁开展儿童 COVID-19 临床试验。
Pediatrics. 2020 Aug;146(2). doi: 10.1542/peds.2020-1081. Epub 2020 May 12.
引用本文的文献
1
The positive impact of COVID-19 on critical care: from unprecedented challenges to transformative changes, from the perspective of young intensivists.新冠疫情对重症监护的积极影响：从前所未有的挑战到变革性变化，以年轻重症医学专家的视角
Ann Intensive Care. 2023 Apr 11;13(1):28. doi: 10.1186/s13613-023-01118-9.
2
Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOVery-SIRIO randomized trial.在有症状的住院非重症监护 COVID-19 患者中用胺碘酮或维拉帕米抑制离子通道：ReCOVery-SIRIO 随机试验。
Cardiol J. 2022;29(5):739-750. doi: 10.5603/CJ.a2022.0072. Epub 2022 Aug 1.
3
Methodological education in response to the quality of COVID-19 publications.针对新冠疫情相关出版物质量的方法学教育
Pharmacol Res. 2021 Feb;164:105381. doi: 10.1016/j.phrs.2020.105381. Epub 2020 Dec 15.
4
From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19.从血管紧张素转换酶 2 破坏到血栓炎症性微血管病：源自 COVID-19 的范例。
Int J Cardiol. 2021 Mar 1;326:243-247. doi: 10.1016/j.ijcard.2020.11.016. Epub 2020 Nov 10.
本文引用的文献
1
Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?COVID-19 临床试验：我们能否更好地利用短暂的机会窗口？
Clin Pharmacol Ther. 2020 Oct;108(4):730-733. doi: 10.1002/cpt.1891. Epub 2020 Jun 12.
2
Coronavirus drugs trials must get bigger and more collaborative.冠状病毒药物试验必须扩大规模并加强合作。
Nature. 2020 May;581(7807):120. doi: 10.1038/d41586-020-01391-9.
3
Waste in covid-19 research.新冠疫情研究中的浪费现象。
BMJ. 2020 May 12;369:m1847. doi: 10.1136/bmj.m1847.
4
Rapid repurposing of drugs for COVID-19.用于治疗新冠肺炎的药物快速重新利用。
Science. 2020 May 22;368(6493):829-830. doi: 10.1126/science.abb9332. Epub 2020 May 8.
5
Randomized Clinical Trials and COVID-19: Managing Expectations.随机临床试验与 COVID-19：合理期待管理
JAMA. 2020 Jun 9;323(22):2262-2263. doi: 10.1001/jama.2020.8115.
Zotero 插件